AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition
…
168,230€
2,65%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
AbbVie keeps Humira market share near 100% despite biosimilars: report
…
Dividendenbekanntmachungen (12.04.2024)
Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBVIE INC US00287Y1091 1,55 USD 1,4449 EUR AMERICAN EQUITY INVESTMENT LIFE HOLDING ... US0256762065…
The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group
AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group are part of the Zacks top Analyst Blog.…
Top Stock Reports for AbbVie, Salesforce & General Electric
Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General…
AbbVie: Still Fits Buffetts 10x EBT Rule Well Despite Guidance Revision
…
Pfizer: AbbVie, Bristol-Myers, Eli Lilly, Johnson & Johnson, Takeda - Die Konkurrenz ist enorm - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…
AbbVie slips after revising guidance to reflect earnings impact
…
Landos Biopharma stock downgraded at H.C. Wainwright amid AbbVie acquisition By Investing.com
Landos Biopharma stock downgraded at H.C. Wainwright amid AbbVie acquisition…
Pharma Stock Roundup: ABBV & NVOs New M&As, FDA Nod to JNJ & MRK PAH Drugs
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves…
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
AbbVie acquisition signals confidence in small-cap biotech sector’s growth potential
AbbVie Inc (NYSE:ABBV)s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development...…
Kurs der AbbVie-Aktie verharrt auf Vortags-Niveau (165,3623 €)
Wenig Kursbewegung gegenwärtig bei der Aktie von AbbVie . Der jüngste Kurs betrug 179,17 US-Dollar. Kaum auffällig ist aktuell an…
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.…
Landos shares rocket 170% on AbbVie takeover deal
…
AbbVie to buy Landos to expand pipeline of immunity-related illnesses By Reuters
AbbVie to buy Landos to expand pipeline of immunity-related illnesses…
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis…
FDA grants full approval to AbbVie/ImmunoGen drug Elahere
…
AbbVie executive sells over $3.7 million in company stock By Investing.com
AbbVie executive sells over $3.7 million in company stock…
Sieg über Parkinson
Am 15. September 2023 erschien der Alzheimer-Aktien-Report von André Fischer, der Biotech-Firmen behandelte, die sich auf die Bereiche Demenz, Parkinson…
The Zacks Analyst Blog Highlights Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez
Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez are included in this Analyst Blog.…
AbbVie CEO marks final year at the helm with $25.7M as pay
…
Top Analyst Reports for Mastercard, AbbVie & Salesforce
Todays Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce,…
Aktie von AbbVie heute am Aktienmarkt kaum gefragt: Kurs fällt (164,7334 €)
Am US-amerikanischen Aktienmarkt liegt das Wertpapier von AbbVie aktuell im Minus. Die Aktie kostete zuletzt 179,37 US-Dollar. Heute hat sich…
AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)
…
Deutsche Biotech-Hoffnung Tubulis holt Top-Investoren an Bord – Börsengang ist "immer eine Option"
Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…
Deutsche Biotech-Hoffnung Tubulis holt Top-Investoren an Bord – Börsengang ist "immer eine Option"
Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…
Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast…
AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease
For Medical and Trade media.
· Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease…
AbbVie Inc. (ABBV) TD Cowen 44th Annual Health Care Conference (Transcript)
…
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
The FDA grants priority review status to Sanofis (SNY) and AbbVies (ABBV) sBLAs for Dupixent and Epkinly, respectively…
AbbVie and OSE Immunotherapeutics ink $713M deal By Investing.com
AbbVie and OSE Immunotherapeutics ink $713M deal…
Healthcare Stocks: 5 Biggest Companies in 2024
Healthcare is one of the worlds most critical sectors, and healthcare stocks offer an opportunity to invest in companies that…
AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports By Reuters
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports…
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…
AbbVie: Pharma-Riese auf Shopping-Tour - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…